Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

l charges

 

.06 

0.16Income related to termination of the exenatide
collaboration with Amylin

 

(0.29) 

(0.43)Earnings per share (non-GAAP)$4.10 to $4.15$3.3921% to 22%The company still anticipates 2013 revenue of between $22.6 billion and $23.4 billion. The company expects overall revenue growth in 2013, driven by a portfolio of products including Humalog, Humulin, Cialis, Strattera, Forteo, Alimta, Cymbalta outside the U.S., Effient, Trajenta and Axiron®, as well as animal health products. In addition, significant revenue growth is expected in the emerging markets, particularly China, while a weaker Japanese yen will dampen revenue growth in Japan. For the fourth quarter of 2013, the company estimates that U.S. sales of Cymbalta will be approximately $500 million, reflecting the loss of U.S. patent exclusivity on December 11, 2013. In addition, this estimate includes substantial reserves for expected future returns of the product. This estimate is subject to variability based upon a variety of factors, including product demand prior to the loss of patent exclusivity, as well as the speed and magnitude of revenue erosion after the loss of patent exclusivity.

The company still anticipates that gross margin as a percent of revenue will be approximately 79 percent.

Marketing, selling and administrative expenses are still expected in the range of $7.0 billion to $7.2 billion. Research and development expenses are still expected to be in the range of $5.3 billion to $5.5 billion.

On a reported basis, other income (expense) is still expected to be in a range between $440 million and $590 million of income in 2013. On a non-GAAP basis, other income (expense) is still expected to be in a range between $50 million of expense to $100 million of income, which excludes $495.4 million of income recognized upon the transfer of exenatide commercial rights outside the U.S. to
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
2. Lilly Declares Fourth-Quarter 2013 Dividend
3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
11. Lilly Reports Second-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 /CNW/ - More than fifty years ago, ... morning sickness in expectant mothers. Tragically, Thalidomide caused serious and ... Support has been provided to survivors over ... Canada in 1991 and settlements from ... a legal obligation to provide support, we have a clear ...
(Date:5/22/2015)... , May 22, 2015 Electrophysiologist ... Institute recently traveled to Boston, MA ... at the 2015 Heart Rhythm Society conference. These ... to focus on the ideas, people and technology ... Convergent is a hybrid, minimally invasive cardiac operation ...
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... approval of Zarxio (filgrastim-sndz) -- the first biosimilar ... -- points toward growth in the ... Information. The mainstream CMO industry is geared to ... infrastructure to produce major biopharmaceutical products. The healthcare ...
Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... 1, 2012  PDI, Inc. (Nasdaq: PDII ) ... and full year 2011 financial results on Wednesday, March ... conference call on Thursday, March 8, at 8:30 am ... March 8, 2012Time:8:30 am Eastern timeDial-in numbers:(866) 644-4654 (U.S. ...
... therapies for foot wounds are saving limbs, restoring mobility, ... who suffer from non-healing foot ulcers. "For ... wounds can be a tremendous problem, making these advanced ... clinical professor of surgery at Yale School of Medicine. ...
Cached Medicine Technology:Advanced Treatments Help Hard-to-Heal Diabetic Foot Ulcers—and Improve Lives 2Advanced Treatments Help Hard-to-Heal Diabetic Foot Ulcers—and Improve Lives 3
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on the ... legislature but which has not been signed to date by ... 449 with overwhelming bipartisan support on April 10, 2015, ... This bill ensures that fracking is prohibited in Maryland through ... of fracking to our water supplies and the air we ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... May 22, 2015 Hundreds of ... behalf of individuals who allegedly experienced serious internal ... continue to move forward in the U.S. District ... Pretrial Order dated May 4, 2015, the Court ... and electronically stored information. Among other things, the ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will likely ... pulmonary disorder (COPD) as the dominant companies like ... well as Germany’s Boehringer Ingelheim compete with each ... market payers, clinicians and patients be disposed to ... new ones? , In spite of recently approved ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow physicians ... D. Leffall, on Monday, May 18, with an 85th ... in the hospital’s Tower Auditorium. Leffall’s younger sister, 83-year-old ... to keep the secret. “I’d like to go in ... know something is up,” she said. , After more ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... Other Providers Would Likely Demand Similar,Treatment Next Year, ... released a new ad today warning policymakers,that other Medicare ... the "same prompt-pay deal" next year if Congress requires,pharmacists ... "Paying one group of Medicare providers twice as ...
... Older people are especially,at risk from heat-related health problems such ... currently experiencing, now is not,the time to do chores, run ... for all ages, but potentially life threatening,for older persons," according ... 10 tips for dealing with a heat wave:, 1. ...
... The 125,000-member American College of Physicians (ACP) today ... the Medicare Improvements for Patients and Providers Act of ... S. 3101 because it addresses and incorporates three of ... MD, FACP, wrote Senator Max Baucus (D-MT), chairman of ...
... June 9 Mylan Inc. (NYSE: MYL ),today ... from the U.S. Food and Drug Administration (FDA) for ... mg and 10,mg., Zaleplon Capsules are the generic ... of approximately $88 million for,the 12 months ending March ...
... donates $100,000 to American Red Cross, INDIANAPOLIS, June ... of Eli Lilly and Company (NYSE: LLY ), ... to aid,Indiana tornado and flood victims. More than 44 ... Mitch Daniels as a result of deadly,tornadoes and severe ...
... MADISON, N.J., June 9 Wyeth (NYSE: ... the Goldman Sachs Twenty-Ninth,Annual Global Healthcare Conference on ... for Wyeth will be Bernard Poussot, President and ... webcast live for investors at, http://www.wyeth.com and ...
Cached Medicine News:Health News:New PCMA Ad: Pharmacist 'Prompt Pay' Will Trigger 'Domino Effect' Among Other Medicare Providers 2Health News:How Seniors Can Beat the Heat 2Health News:ACP pledges support for Medicare improvements for Patients and Providers Act of 2008 2Health News:Lilly to Provide Aid to Indiana Tornado and Flood Victims 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: